• News
  • BioTech

Sialix changes name to Siamab, adds $2M to Series B

Sialix Inc., a biotechnology company developing cancer immunotherapies, has changed its name to Siamab Therapeutics. The company also has received an additional $2 million in funding as part of its Series B, bringing the total raised to $6 million.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!